Nitisinone causes acquired tyrosinosis in alkaptonuria
- 1 September 2020
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 43 (5), 1014-1023
- https://doi.org/10.1002/jimd.12229
Abstract
For over two decades, nitisinone (NTBC) has been successfully used to manipulate the tyrosine degradation pathway and save the lives of many children with hereditary tyrosinaemia type 1. More recently, NTBC has been used to halt homogentisic acid accumulation in alkaptonuria (AKU) with evidence suggesting its efficacy as a disease modifying agent. NTBC-induced hypertyrosinaemia has been associated with cognitive impairment and potentially sight-threatening keratopathy. In the context of a non-lethal condition (ie, AKU), these serious risks call for an evaluation of the wider impact of NTBC on the tyrosine pathway. We hypothesised that NTBC increases the tyrosine pool size and concentrations in tissues. In AKU mice tyrosine concentrations of tissue homogenates were measured before and after treatment with NTBC. In humans, pulse injection withl-[C-13(9)]tyrosine andl-[d(8)]phenylalanine was used along with compartmental modelling to estimate the size of tyrosine pools before and after treatment with NTBC. We found that NTBC increased tyrosine concentrations in murine tissues by five to nine folds. It also significantly increased the tyrosine pool size in humans (P < .001), suggesting that NTBC increases tyrosine not just in serum but also in tissues (ie, acquired tyrosinosis). This study provides, for the first time, the experimental proof for the magnitude of NTBC-related acquired tyrosinosis which should be overcome to ensure the safe use of NTBC in AKU.Funding Information
- Association for Clinical Biochemistry and Laboratory Medicine (ACB scientific scholarship award 2017)
This publication has 31 references indexed in Scilit:
- Ochronotic pigmentation is caused by homogentisic acid and is the key event in alkaptonuria leading to the destructive consequences of the disease—A reviewJournal of Inherited Metabolic Disease, 2019
- Subclinical ochronosis features in alkaptonuria: a cross-sectional studyBMJ Innovations, 2019
- Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria CentreMolecular Genetics and Metabolism, 2018
- Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric MicePublished by Springer Science and Business Media LLC ,2015
- Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatmentAnnals Of The Rheumatic Diseases, 2014
- Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinoneAnnals Of The Rheumatic Diseases, 2013
- Recent advances in management of alkaptonuria (invited review; best practice article)Journal of Clinical Pathology, 2013
- A 3-year randomized therapeutic trial of nitisinone in alkaptonuriaMolecular Genetics and Metabolism, 2011
- Oxidation of homogentisic acid to ochronotic pigment in connective tissueBiochimica et Biophysica Acta (BBA) - General Subjects, 1969
- Biochemical, pathologic and clinical aspects of alcaptonuria, ochronosis and ochronotic arthropathy: Review of world literature (1584–1962)The American Journal of Medicine, 1963